Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.67 |
| ▸ | GRM6 | O15303 | 1/20 | 0.67 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.67 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.67 |
| ▸ | GSR | P00390 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.67 |
| ▸ | GRM5 | P41594 | 1/20 | 0.67 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.67 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.67 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.67 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.67 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.67 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.67 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.67 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.67 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.67 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Myristic Acid SCHEMBL28211043 | 1.00 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Dodecanoate SCHEMBL28392111 | 1.00 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Octanoic Acid SCHEMBL28246078 | 1.00 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Decanoic Acid SCHEMBL1045578 | 1.00 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Palmitic Acid SCHEMBL4391707 | 1.00 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Palmitic Acid SCHEMBL4391708 | 1.00 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Stearic Acid SCHEMBL4391220 | 1.00 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Dodecanoate SCHEMBL28371028 | 1.00 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Decanoic Acid SCHEMBL6751319 | 1.00 | GRM8 (0.67) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Decanoic Acid SCHEMBL13278749 | 0.98 | GRM8 (0.64) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697774-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3654969-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3634402-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2019079760-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019018353-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2019018395-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-24 | — | — | WO | disclosed |
| US-10175233-B2 | Biomarkers for cardiovascular diseases and methods using the same | METABOLON, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2018227049-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-12-13 | — | — | WO | disclosed |
| US-20160178620-A1 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and other Metabolic-Syndrome Related Disorders and Methods Using the Same | METABOLON, INC. | 2016-06-23 | — | — | US | disclosed |
| US-9250225-B2 | Biomarkers for insulin resistance and methods using the same | METABOLON, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-0708765-A1 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO. INC. (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996009824-A1 | METHOD FOR IMPROVING REPRODUCTIVE EFFICIENCY IN FARM ANIMALS | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1996008239-A1 | USE OF 5-ALPHA-REDUCTASE INHIBITORS TO INCREASE HDL CHOLESTEROL LEVELS | MERCK & CO., INC. (US) | 1996-03-21 | — | — | WO | disclosed |
| EP-0663827-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0663827-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-07-26 | — | — | EP | disclosed |
| WO-1995002607-A1 | 7-SUBSTITUTED-Δ4-6-AZASTEROID DERIVATIVES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1995002587-A1 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994021614-A1 | SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994007496-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| WO-1993006092-A1 | PIPERAZINYL (SULFONYL)AMIDE DERIVATIVES OF CAMPHOR AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1993-04-01 | — | — | WO | disclosed |